Identification and consequences of galectin-3 expression in pituitary tumors

Mol Cell Endocrinol. 2010 Sep 15;326(1-2):8-14. doi: 10.1016/j.mce.2010.04.026. Epub 2010 May 6.

Abstract

Although the mechanisms regulating pituitary tumor development and progression are still unclear, new information on the molecular mechanisms involved in the pathogenesis of human pituitary tumors have accumulated. Recent evidence suggests that galectin-3 plays an important role in pituitary tumorigenesis and in tumor progression. Galectin-3 is expressed in a variety of tumors and the intensity of expression and localization depend on tumor progression, invasiveness and metastatic potential. Galectin-3 expression has been used as a potential diagnostic and/or prognostic marker in a variety of neoplasms. This review summarizes existing information regarding the structural and functional properties of galectin-3 protein as well as the LGALS3 gene in pituitary tumorigenesis. Given its role in pituitary tumor cell proliferation and in apoptosis, galectin-3 may be a target for the treatment of aggressive pituitary tumors.

Publication types

  • Review

MeSH terms

  • Adrenocorticotropic Hormone / metabolism
  • Animals
  • Apoptosis / genetics
  • Carcinoma / pathology
  • Core Binding Factor Alpha 1 Subunit / metabolism
  • Core Binding Factor Alpha 2 Subunit / metabolism
  • Galectin 3 / biosynthesis
  • Galectin 3 / metabolism*
  • Humans
  • Methylation
  • Mice
  • Pituitary Gland / pathology
  • Pituitary Neoplasms / genetics
  • Pituitary Neoplasms / metabolism*
  • Pituitary Neoplasms / pathology

Substances

  • Core Binding Factor Alpha 1 Subunit
  • Core Binding Factor Alpha 2 Subunit
  • Galectin 3
  • RUNX1 protein, human
  • RUNX2 protein, human
  • Adrenocorticotropic Hormone